Hikma signs exclusive licensing, distribution and supply agreement with Basilea for Cresemba
Cresemba (isavuconazole) is an injectable and oral anti-fungal product.
Hikma Pharmaceuticals has extended its current exclusive licensing, supply and distribution agreement with biopharmaceutical company, Basilea Pharmaceutica International, for its anti-infective product Zevtera (ceftobiprole), to also include Basilea’s injectable and oral anti-fungal product Cresemba (isavuconazole).
Under the terms of the amended agreement, Hikma will have the exclusive rights to register, distribute and market Cresemba in all its MENA markets leveraging Hikma’s strong local presence, sales and marketing capabilities and regulatory expertise.
Cresemba has received approvals across Europe and the US. In March 2015, the product was approved by the FDA for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis. The European marketing authorisation was granted in October 2015 to isavuconazole for the treatment of adult patients with invasive aspergillosis and for the treatment of adult patients with mucormycosis for whom amphotericin B is inappropriate.
Mazen Darwazah, Vice Chairman and CEO of MENA and Emerging Markets said: “We are delighted to be building on our partnership with Basilea enabling us to continue enhancing our growing portfolio of high value products in the MENA and reinforcing our commitment to increasing patients’ access to high-quality medicines.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.